Pharmacokinetics of escalating single-dose administration of cannabidiol to cats.

Autor: Rozental AJ; From the Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University Veterinary, Fort Collins, Colorado, USA., Gustafson DL; From the Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University Veterinary, Fort Collins, Colorado, USA., Kusick BR; From the Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University Veterinary, Fort Collins, Colorado, USA., Bartner LR; From the Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University Veterinary, Fort Collins, Colorado, USA., Castro SC; From the Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University Veterinary, Fort Collins, Colorado, USA., McGrath S; From the Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University Veterinary, Fort Collins, Colorado, USA.
Jazyk: angličtina
Zdroj: Journal of veterinary pharmacology and therapeutics [J Vet Pharmacol Ther] 2023 Jan; Vol. 46 (1), pp. 25-33. Date of Electronic Publication: 2022 Oct 27.
DOI: 10.1111/jvp.13100
Abstrakt: This study aimed to assess the single-dose pharmacokinetics and tolerability of a cannabidiol (CBD) isolate in sunflower oil with escalating oral doses in eight healthy, purpose-bred cats. Eight cats were randomized into six dosing groups of four cats each. Cats were administered a single 2.5, 5, 10, 20, 40, or 80 mg/kg dose orally with at least a two-week washout in between doses. Behavior scoring, complete blood count, serum biochemistry analysis, physical examination, and CBD plasma levels were evaluated before and after dosing. All cats successfully completed the study. CBD was measured in the plasma of all cats dosed with CBD oil. The Cmax and AUC increased in a dose-proportional fashion across all dosing groups. There were no major bloodwork or behavioral changes although the BUN and creatinine values decreased after treatment across all doses. No adverse effects were observed, and behavioral changes were limited to head shaking, lip smacking, and hypersalivation immediately following dose administration. Single orally administered CBD doses up to 80 mg/kg were safe and well tolerated in this cohort of cats and display dose-proportional pharmacokinetics across a broad concentration.
(© 2022 The Authors. Journal of Veterinary Pharmacology and Therapeutics published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: